Xtalks Life Science Podcast

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.

Xtalks Life Science Podcast is a science podcast hosted by Xtalks, with 260 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Xtalks hosts Xtalks Life Science Podcast, a science show with 260 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #264

  Why Gout Is Often Misunderstood: Treatment and Research with Crystalys Therapeutics’ James Mackay

  Aug 5, 202624 minS1

  In this week’s episode of the Xtalks Life Science Podcast, host Soumya Shashikumar, Senior Life Sciences Journalist at Xtalks, spoke with James Mackay, CEO of Crystalys Therapeutics, about gout, persistent misconceptions surrounding the condition and current clinical research. Gout is often linked primarily to diet and alcohol. James explains that many patients instead have difficulty removing enough uric acid from the body, allowing crystals to accumulate in the joints and contribute to inflammation over time. The conversation examines the stigma this misunderstanding can create. James shares why some people may avoid discussing their condition or seeking care because they feel blamed for developing it. He also discusses difficult-to-treat gout, the limitations of current treatment options and how researchers are studying outcomes that may be more meaningful to patients. Tune in to learn more about why gout remains widely misunderstood, the gaps in current care and the challenges of developing treatments for patients with limited options. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

  ListenShow Notes
• 

  Episode #263

  Addressing Neonatal Brain Injury: HIE Treatment Development with ReAlta Life Sciences’ Dr. Kia Motesharei

  Jul 24, 202634 minS1

  In this week’s episode of the Xtalks Life Science Podcast, host Soumya Shashikumar, Senior Life Sciences Journalist at Xtalks, spoke with Dr. Kia Motesharei, President and Chief Operating Officer of ReAlta Life Sciences, about hypoxic-ischemic encephalopathy (HIE) and efforts to develop treatments beyond therapeutic hypothermia. HIE is a serious neonatal brain injury caused by insufficient oxygen and blood flow to the brain around the time of birth. Therapeutic hypothermia, or controlled cooling, can help limit inflammation and secondary injury, but there are currently no approved drug therapies for HIE. Dr. Motesharei explains how reperfusion injury can occur when blood flow returns to the brain after oxygen deprivation, triggering an inflammatory cascade that may contribute to further tissue damage. He also discusses why targeting more than one inflammatory pathway may be important and how ReAlta’s investigational approach is intended to address both complement- and neutrophil-driven inflammation. The conversation explores the challenges of neonatal clinical trials, where clinicians may have only hours to identify eligible newborns, explain the research and obtain informed consent from families facing an acute medical crisis. Because newborns have not yet developed the motor and cognitive abilities used to assess treatments in older patients, early MRI may help measure brain injury while longer-term follow-up evaluates developmental outcomes. Tune in to learn more about HIE, the narrow intervention window in neonatal trials and efforts to develop treatments that could reduce brain injury in newborns. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

  ListenShow Notes
• 

  Episode #262

  Why Endometriosis Needs New Treatment Approaches with EndoCyclic Therapeutics’ Dr. Tanya Petrossian

  Jul 8, 202628 minS1

  In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Dr. Tanya Petrossian, CEO and Founder of EndoCyclic Therapeutics, a biopharmaceutical company developing a non-hormonal therapeutic approach for endometriosis. Endometriosis affects many women, but it is still often difficult to diagnose, treat and fully understand. For many patients, available treatment options have historically centered on hormone-based therapies or surgery, leaving significant unmet needs in long-term care. In this episode, Dr. Petrossian discusses the patient burden of endometriosis and why the condition has remained challenging to diagnose and treat. She also shares how her own experience with delayed diagnosis helped shape her understanding of the gaps patients face and ultimately contributed to her decision to start EndoCyclic Therapeutics. The conversation explores why innovation has lagged in endometriosis, despite the condition’s significant impact on patients’ lives. Dr. Petrossian discusses the need for new treatment options, including approaches that do not rely on hormones, and explains at a high level how EndoCyclic Therapeutics’ work is designed to target disease biology. Dr. Petrossian also discusses the broader challenges and opportunities of building a company in women’s health, including the progress being made in endometriosis research and the continued need for greater recognition, investment and clinical innovation. Tune in to learn more about endometriosis, the need for new treatment approaches and what progress in women’s health innovation could look like in the years ahead. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

  ListenShow Notes
• 

  Episode #261

  Precision Oncology in Lung Cancer with Boehringer Ingelheim’s Itziar Canamasas and Volker Teichgräber

  Jun 24, 202626 minS1

  In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with two experts from Boehringer Ingelheim: Itziar Canamasas, PhD, Global Head of Oncology and Senior Vice President, and Volker Teichgräber, MD, Senior Vice President and Head of Global Experimental Medicine Oncology. The conversation focused on how precision oncology is changing the way advanced non-small cell lung cancer (NSCLC) is diagnosed, studied and treated. As molecular testing becomes increasingly important in lung cancer care, identifying specific genomic alterations early in the treatment journey can help inform treatment decisions and support more personalized approaches for patients. In this episode, Itziar discusses how advanced NSCLC care has evolved over the past decade and why molecular testing is central to the future of precision oncology. She also shares her perspective on the unmet needs facing patients with rare molecularly defined forms of lung cancer, including HER2-mutant NSCLC. Volker discusses the R&D considerations involved in studying rare genomic subtypes of NSCLC. He explains what researchers consider when translating early clinical findings into later-stage studies. The conversation also explores how clinical trial design is evolving in precision oncology, including the need to balance scientific rigor with the practical realities of studying rare patient groups. Itziar and Volker also discuss what may matter most for improving outcomes in advanced NSCLC and other molecularly defined cancers, from earlier testing and targeted treatment strategies to continued advances in translational medicine, biomarkers and clinical research. Tune in to learn more about precision oncology in advanced NSCLC, the role of molecular testing and the challenges of developing targeted therapies for rare genomic subtypes. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

  ListenShow Notes
• 

  Episode #259

  Sustainability in Asthma and COPD Drug Development with Chiesi’s Diego Ardigò

  Jun 10, 202624 minS1

  In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Diego Ardigò, Executive Vice President, Global R&D at Chiesi, a biopharma company focused on respiratory health, rare diseases and specialty care. Respiratory medicine presents unique drug development challenges because successful therapies depend not only on the drug itself, but also on the formulation and delivery device. As innovation continues across asthma and chronic obstructive pulmonary disease (COPD), developers must balance performance, usability, sustainability and continuity of care. In this episode, Diego discusses how Chiesi approaches innovation in respiratory disease drug development and why developing inhaled therapies requires careful integration of drug formulation, device design and patient experience. The conversation also explores the growing focus on sustainability in respiratory care. Diego discusses how the industry can transition toward more environmentally sustainable inhaler options while maintaining treatment continuity for patients who are stable on their current therapies. In addition, Diego discusses the role of inhaler technique, patient behavior and long-term treatment adherence in shaping R&D decisions. Diego also explains why respiratory medicine offers valuable lessons for the broader pharmaceutical industry in balancing innovation, sustainability and patient-centered care. Tune in to learn more about the future of asthma and COPD drug development and how respiratory medicine is evolving to meet both patient and sustainability goals. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

  ListenShow Notes

Recent guests on Xtalks Life Science Podcast. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.